Literature DB >> 7742150

Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.

G P Todd1, I G Chadwick, K S Higgins, W W Yeo, P R Jackson, L E Ramsay.   

Abstract

1. The effects of a single oral dose of enalapril 10 mg on serum ACE activity and blood pressure in relation to the ACE genotype were studied in 27 healthy men, n = 9 each of genotype DD, ID and II, in a parallel group study design. 2. Before treatment serum ACE activity differed significantly between the genotypes, with serum ACE activity 56% higher in DD than II subjects, and the genotype explaining 40% of between-subject variance in serum ACE activity. 3. After oral enalapril 10 mg the absolute fall in serum ACE activity was significantly larger in DD than II subjects at 2, 4, and 6 h (by 9.0 (95% CI 0.7-17.2), 10.7 (3.8-17.6), and 9.7 (2.8-16.6) nmol ml-1 min-1 respectively), but not at 24 h (fall in II > DD by 1.1 (-8.9 to 6.7) nmol ml-1 min-1). 4. Serum ACE activity remained significantly related to the ACE genotype at each time-point after enalapril, with the genotype explaining 22-46% of between-subject variance in serum ACE. 5. Falls in mean arterial pressure in response to enalapril were not significantly related to the ACE genotype, with the average fall over 6 h in DD > II genotype by 0.7 mm Hg (95% CI -5.5 to 4.1). 6. Blood pressure responses to enalapril did not correlate significantly with the initial serum ACE, or the absolute or percent reductions in serum ACE activity after enalapril.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742150      PMCID: PMC1364949          DOI: 10.1111/j.1365-2125.1995.tb04419.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Myocardial infarction. The ACE of hearts.

Authors:  T W Kurtz
Journal:  Nature       Date:  1992-10-15       Impact factor: 49.962

2.  A sensitive fluorimetric assay for serum angiotensin-converting enzyme.

Authors:  J Friedland; E Silverstein
Journal:  Am J Clin Pathol       Date:  1976-08       Impact factor: 2.493

3.  Molecular biology of the renin cascade in hypertension. Report of a meeting of physicians and scientists, University of Leicester.

Authors: 
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

4.  Kindred hearts and coronaries.

Authors:  E Espiner
Journal:  Lancet       Date:  1993-04-17       Impact factor: 79.321

5.  Clinical evaluation of Dinamap 845 automated blood pressure recorder.

Authors:  J H Silas; A T Barker; L E Ramsay
Journal:  Br Heart J       Date:  1980-02

Review 6.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

7.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.

Authors:  F Cambien; O Poirier; L Lecerf; A Evans; J P Cambou; D Arveiler; G Luc; J M Bard; L Bara; S Ricard
Journal:  Nature       Date:  1992-10-15       Impact factor: 49.962

8.  Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension.

Authors:  R Y Zee; Y K Lou; L R Griffiths; B J Morris
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

9.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

10.  Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.

Authors:  C I Johnston; B Jackson; B McGrath; G Matthews; L Arnolda
Journal:  J Hypertens Suppl       Date:  1983-10
View more
  7 in total

Review 1.  Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.

Authors:  Tianhua Niu; Xiu Chen; Xiping Xu
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Gene markers and antihypertensive therapy.

Authors:  Stephen T Turner; Gary L Schwartz
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

3.  Pharmacogenetics of cardiovascular drug therapy.

Authors:  Bas J M Peters; Olaf H Klungel; Anthonius de Boer; Bruno H Ch Stricker; Anke-Hilse Maitland-van der Zee
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

4.  Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.

Authors:  E Katriina Tarkiainen; Aleksi Tornio; Mikko T Holmberg; Terhi Launiainen; Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

5.  The higher exercise intensity and the presence of allele I of ACE gene elicit a higher post-exercise blood pressure reduction and nitric oxide release in elderly women: an experimental study.

Authors:  Hugo A P Santana; Sérgio R Moreira; Willson B Neto; Carla B Silva; Marcelo M Sales; Vanessa N Oliveira; Ricardo Y Asano; Foued S Espíndola; Otávio T Nóbrega; Carmen S G Campbell; Herbert G Simões
Journal:  BMC Cardiovasc Disord       Date:  2011-12-02       Impact factor: 2.298

6.  ACE genotype, risk and causal relationship to stroke: implications for treatment.

Authors:  Agnieszka Slowik; Tomasz Dziedzic; Joanna Pera; Dorota Wloch; Grzegorz Kopec; Andrzej Szczudlik
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-06

7.  Novel Natural Angiotensin Converting Enzyme (ACE)-Inhibitory Peptides Derived from Sea Cucumber-Modified Hydrolysates by Adding Exogenous Proline and a Study of Their Structure⁻Activity Relationship.

Authors:  Jianpeng Li; Zunying Liu; Yuanhui Zhao; Xiaojie Zhu; Rilei Yu; Shiyuan Dong; Haohao Wu
Journal:  Mar Drugs       Date:  2018-08-04       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.